Myriad Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Myriad Pharmaceuticals.

Results 1 - 20 of 74 in Myriad Pharmaceuticals

  1. Biotech reels over patent rulingRead the original story w/Photo

    Tuesday Jul 8 | NatureNews

    Guidelines that forbid patents on a wide array of natural products, phenomena and principles have many in the biotechnology and pharmaceutical industries worried about the future of their business.

    Comment?

  2. Novo, Other Medicals Display Healthy ActionRead the original story

    Thursday Jun 26 | Investor's Business Daily

    Leaders in buy range could get tougher to find as the market uptrend continues and stocks break out to new highs .

    Comment?

  3. France Biotech Introduces Its New Board of Directors, Elected During Its Annual General Meeting on June 12, 2014Read the original story

    Tuesday Jun 17 | Freshnews

    France Biotech , an association of entrepreneurs in the life sciences industry, announced the election of its new board of directors, chaired by Pierre-Olivier Goineau, following its annual general meeting on Thursday, June 12, at the Yacht Club de Paris.

    Comment?

  4. France Biotech Introduces Its New Board of Directors, Elected During...Read the original story

    Tuesday Jun 17 | Business Wire

    France Biotech , an association of entrepreneurs in the life sciences industry, announced the election of its new board of directors, chaired by Pierre-Olivier Goineau, following its annual general meeting on Thursday, June 12, at the Yacht Club de Paris.

    Comment?

  5. Crescendo Bioscience to present multiple studies at 2014 EULAR MeetingRead the original story

    Jun 9, 2014 | EurekAlert!

    Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced that Vectra DA data will be featured in eight posters at the 2014 European League Against Rheumatism Annual Meeting, June 11-14, 2014, in Paris, France.

    Comment?

  6. Cancer-gene data sharing boostedRead the original story w/Photo

    Jun 10, 2014 | NatureNews

    When the US diagnostics giant Myriad Genetics had its legal monopoly on breast-cancer gene testing eliminated one year ago, the company still retained an enormous edge over competitors.

    Comment?

  7. Myriad Genetics Director Unloads $178,500 in StockRead the original story w/Photo

    Jun 6, 2014 | AmericanBankingNews.com

    Myriad Genetics Director John T. Henderson sold 5,000 shares of the stock in a transaction dated Thursday, June 5th.

    Comment?

  8. Shuwen Biotech And DiagnoCure Sign Exclusive License And...Read the original story

    Jun 5, 2014 | BioSpace

    Shuwen Biotech Co. Ltd., a diagnostic company focused on licensing, developing and commercializing diagnostic kits and services for unmet clinical needs in China, has announced today that it has formed an alliance with the Canada-based DiagnoCure, Inc. to commercialize the Previstagea GCC colorectal cancer staging test in China.

    Comment?

  9. Shuwen Biotech and DiagnoCure Sign Exclusive License and Collaboration Agreement for ...Read the original story

    Jun 6, 2014 | B3C

    Shuwen Biotech Co. Ltd. , a diagnostic company focused on licensing, developing and commercializing diagnostic kits and services for unmet clinical needs in China, has announced today that it has formed an alliance with the Canada-based DiagnoCure, Inc. to commercialize the Previstage GCC colorectal cancer staging test in China.

    Comment?

  10. Pathway Genomics offers BRCA cancer testRead the original story

    Jun 3, 2014 | The San Diego Union-Tribune

    Jim Plante, Pathway Genomics founder and CEO, right, and Ardy Arianpour, chief strategy officer, hold the company's new test for the BRCA mutations associated with various cancers.

    Comment?

  11. Myriad myPath melanoma test improves the reliability of melanoma diagnosisRead the original story

    Feb 6, 2014 | Science, Industry and Business

    Myriad Genetics, Inc. today presented results from a pivotal clinical validation study of the Myriad myPatha Melanoma test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Ill.

    Comment?

  12. Myriad presents clinical data on Myriad myRisk Hereditary Cancer Test at ASCORead the original story

    Jun 1, 2014 | EurekAlert!

    Myriad Genetics, Inc. today presented several clinical studies on the Myriad myRisk Hereditary Cancer test at the 2014 American Society of Clinical Oncology annual meeting in Chicago, Illinois.

    Comment?

  13. Myriad presents data on BRACAnalysis CDx and HRD at 2014 ASCO meetingRead the original story

    May 29, 2014 | EurekAlert!

    Myriad Genetics, Inc. , a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology meeting this week that supports the clinical efficacy of its BRACAnalysis CDx and HRD tests in predicting platinum based therapy response for breast cancer patients.

    Comment?

  14. Prolaris test predicts mortality risk in prostate cancer biopsy studyRead the original story

    May 19, 2014 | EurekAlert!

    Myriad Genetics, Inc. today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association Annual Meeting in Orlando, Fla.

    Comment?

  15. Short Interest in Myriad Genetics Decreases By 3.8%Read the original story w/Photo

    May 19, 2014 | AmericanBankingNews.com

    Myriad Genetics was the target of a significant drop in short interest in April.

    Comment?

  16. United States (USA)-Molecular Diagnostics Market, Test Volume Forecast...Read the original story

    May 14, 2014 | PRWeb

    Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being added continuously.

    Comment?

  17. DGAP-News: Crescendo Bioscience's Vectra(R) DA Predicts Radiographic...Read the original story

    May 14, 2014 | GlobeNewswire

    News: Myriad Genetics, Inc. / Crescendo Bioscience's Vectra DA Predicts Radiographic Progression in Patients With Early Rheumatoid Arthritis 14.05.2014 / 13:05 New Study Data Published in Annals of Rheumatic Diseases Add to Clinical Evidence SALT LAKE CITY, 2014-05-14 13:05 CEST ... (more)

    Comment?

  18. Crescendo Bioscience's Vectra(R) DA Predicts Radiographic Progression ...Read the original story

    May 14, 2014 | GlobeNewswire

    Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced the online publication of a new study in the journal Annals of the Rheumatic Diseases for Crescendo's Vectra DA blood test.

    Comment?

  19. United States - Molecular Diagnostics Market: USA Test Volume Forecast & CompaniesRead the original story

    May 12, 2014 | SBWire

    Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being added continuously.

    Comment?

  20. Counsyl raises $28 million for genetic screening testRead the original story

    May 9, 2014 | Business Journal

    Genetic testing company Counsyl Inc. raised $28 million in a Series D investment, the company said Thursday, part of a wave of genetic testing companies hoping to screen potential parents and others for cancer and other diseases.

    Comment?